Detalhe da pesquisa
1.
Genomics to select treatment for patients with metastatic breast cancer.
Nature
; 610(7931): 343-348, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071165
2.
Author Correction: Genomic characterization of metastatic breast cancers.
Nature
; 572(7767): E7, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31308536
3.
Genomic characterization of metastatic breast cancers.
Nature
; 569(7757): 560-564, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31118521
4.
p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane.
Br J Cancer
; 130(4): 613-619, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38182687
5.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161271
6.
Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer.
Br J Cancer
; 129(9): 1516-1523, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37697030
7.
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Ann Surg
; 277(1): e153-e161, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534229
8.
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
Oncologist
; 28(10): e867-e876, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589218
9.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825569
10.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36988749
11.
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and Number.
J Immunol
; 206(10): 2265-2270, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33931486
12.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526149
13.
Association of chemotherapy and comorbidities with overall survival in elderly patients with early breast cancer: a French population-based propensity score-matched analysis.
Int J Clin Oncol
; 28(3): 371-381, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36645534
14.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183733
15.
Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS.
Anal Chem
; 94(16): 6297-6303, 2022 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35416669
16.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687411
17.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382554
18.
Impact of early palliative care on additional line of chemotherapy in metastatic breast cancer patients: results from the randomized study OSS.
Support Care Cancer
; 31(1): 82, 2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574052
19.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794206
20.
Treatment strategies for breast cancer brain metastases.
Br J Cancer
; 124(1): 142-155, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33250512